ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
83.12
+2.44 (+3.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close80.68
Open81.45
Bid70.00 x 800
Ask83.00 x 800
Day's Range79.00 - 83.18
52 Week Range60.27 - 153.99
Volume1,062,959
Avg. Volume940,626
Market Cap8.398B
Beta (3Y Monthly)2.70
PE Ratio (TTM)N/A
EPS (TTM)-6.97
Earnings DateFeb 6, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est121.17
Trade prices are not sourced from all markets
  • Business Wire20 hours ago

    Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTRO®, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. “Our partnership with Medison marks an important step in our global commercial expansion and signals our intent to ensure that patients suffering from serious rare diseases have access to our medicines, regardless of location,” said Theresa Heggie, SVP and Head of Europe, Middle East and Africa, and Canada, Alnylam Pharmaceuticals.

  • Markit3 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    # Alnylam Pharmaceuticals Inc ### NASDAQ/NGS:ALNY View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining ## Bearish sentiment Short interest | Positive Short interest is low for ALNY with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 15. ## Money flow ETF/Index ownership | Positive ETF activity is positive but appears to be weakening. Over the last month, growth of ETFs holding ALNY is favorable, with net inflows of $6.61 billion. This is among the highest periods of net inflows seen over the last one-year, but the rate of additional flows appears to be decreasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire6 days ago

    New Research Coverage Highlights Gentex, Tenneco, Mercury General, MGM Resorts International, ResMed, and Alnylam Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, Jan. 16, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Pfizer Gets FDA's Priority Review for Rare Disease Candidate
    Zacks7 days ago

    Pfizer Gets FDA's Priority Review for Rare Disease Candidate

    FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

  • Business Wire7 days ago

    Alnylam Pharmaceuticals Prices Public Offering of Common Stock

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $77.50 per share. The gross proceeds to Alnylam from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $387,500,000. The offering is expected to close on or about January 17, 2019, subject to the satisfaction of customary closing conditions.

  • This Biotech Stock Plunged On Its Looming Rivalry With Pfizer
    Investor's Business Daily7 days ago

    This Biotech Stock Plunged On Its Looming Rivalry With Pfizer

    Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.

  • Business Wire7 days ago

    Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock. In addition, Alnylam has granted the underwriter a 30-day option to purchase up to an additional 750,000 shares of its common stock solely to cover over-allotments. Barclays Capital Inc. is acting as sole book-running manager for the offering.

  • Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
    Zacks13 days ago

    Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus

    It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.

  • 3 Things Alnylam's Management Wants You to Know
    Motley Fool13 days ago

    3 Things Alnylam's Management Wants You to Know

    The biotech gave investors reasons to cheer at the J.P. Morgan Healthcare Conference

  • Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
    Zacks14 days ago

    Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4

    Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.

  • Sales of Alnylam's first drug beat expectations in final quarter of 2018
    American City Business Journals15 days ago

    Sales of Alnylam's first drug beat expectations in final quarter of 2018

    The announcement commanded investor's attention to kick off the weeklong JP Morgan Healthcare conference.

  • Business Wire15 days ago

    Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today pre-announced its unaudited fourth quarter 2018 global net product revenues for ONPATTRO and provided additional updates on the product’s commercial launch. ONPATTRO global net product revenues (unaudited) for the fourth quarter of 2018 were $11-12 million. As of year-end 2018, over 200 patients in the U.S. and EU were receiving commercial ONPATTRO treatment, and approximately 550 total patients worldwide, including patients on commercial drug and patients in clinical studies and in the Company’s global Expanded Access Program (EAP), were being treated with patisiran.

  • Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018
    Investor's Business Daily19 days ago

    Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018

    The Food and Drug Administration approved 59 new drugs in 2018 — hitting at least a four-year record — though fewer biologic drugs passed muster. There were also 17 biologic drugs approved.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit21 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire25 days ago

    Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 10:30 am PT (1:30 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on unaudited fourth quarter 2018 global net product revenues for ONPATTRO® (patisiran) as well as additional updates on the product’s commercial launch. In addition, the Company will webcast the Q&A breakout session immediately following its presentation at 11:00 am PT (2:00 pm ET).

  • Alnylam (ALNY) Surges: Stock Moves 8.7% Higher
    Zacks26 days ago

    Alnylam (ALNY) Surges: Stock Moves 8.7% Higher

    Alnylam (ALNY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit29 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on December 20. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Business Wirelast month

    Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Alnylam Pharmaceuticals, Inc. have sued Alnylam officers and directors for alleged violations of the Securities Exchange Act of 1934 between February 15, 2018 and September 12, 2018.

  • Motley Foollast month

    RNAi Goes Big-Time in 2018

    A first-in-kind FDA approval catapulted this treatment approach into the spotlight.

  • Benzingalast month

    Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved

    Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...

  • Motley Foollast month

    Top 10 Healthcare Stories of 2018

    New drugs, trial flops, M&A, and a little bit of everything else that happened in healthcare in 2018.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma

    NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...

  • 5 Top Drug/Biotech Merger & Acquisition Targets for 2019
    Zackslast month

    5 Top Drug/Biotech Merger & Acquisition Targets for 2019

    Here are five stocks that are attractive and most likely to be takeout targets in 2019.

  • Business Wirelast month

    Alnylam Announces Settlement of Litigation with Silence Therapeutics

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics. The settlement allows Alnylam to avoid the costs and distraction associated with continued litigation in multiple countries. Under terms of the global settlement, Silence will receive a low royalty on annual net sales of ONPATTRO in the EU only, with tiered royalties of 0.33 percent to 1.0 percent through 2023. Further terms of the agreement include the grant from Silence to Alnylam of a non-exclusive, global irrevocable, license to all relevant patents and for all current and future Alnylam products, whether commercialized by Alnylam or a collaborator or licensee (including ONPATTRO, vutrisiran, givosiran, lumasiran, inclisiran, fitusiran, cemdisiran, ALN-HBV02, ALN-AAT02, and all other investigational therapeutics in Alnylam’s current and future pipeline).

  • Hedge Funds Are Dumping Alnylam Pharmaceuticals, Inc. (ALNY)
    Insider Monkeylast month

    Hedge Funds Are Dumping Alnylam Pharmaceuticals, Inc. (ALNY)

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]